MorphoSys To Participate in UBS Global Healthcare Conference

Rhea-AI Summary

MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will have its CEO, Jean-Paul Kress, participate in a fireside chat at the UBS Global Healthcare Conference on May 25, 2021, at 7:00 a.m. Eastern Time. The live audio can be accessed from the company’s website, with a replay available afterward. MorphoSys is focused on innovative therapies for cancer and autoimmune diseases, boasting a successful track record with products like Monjuvi (accelerated approval by the FDA in July 2020) and Tremfya (first regulatory approval in 2017). More details are available at morphosys.com.

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., the company's Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday May 25, 2021 at 7:00 a.m. Eastern Time.

Live audio of the fireside chat can be accessed from the Media and Investors section under Conferences on MorphoSys' website, www.morphosys.com. A replay of the webcast will also be available on MorphoSys' website.

About MorphoSys
MorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies which are developed by partners in different areas of unmet medical need. In 2017, Tremfya^(R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of MorphoSys' proprietary product Monjuvi^(R) (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma.

Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has more than 600 employees. More information at www.morphosys.com or www.morphosys-us.com.

Monjuvi^(R) is a registered trademark of MorphoSys AG.
Tremfya^(R) is a registered trademark of Janssen Biotech, Inc.

For more information, please contact:

Media Contacts: Thomas Biegi Vice President Tel.: +49 (0)89 / 89927 26079 thomas.biegi@morphosys.com	Investor Contacts: Dr. Julia Neugebauer Senior Director Tel: +49 (0)89 / 899 27 179 julia.neugebauer@morphosys.com
Jeanette Bressi Director, US Communications Tel: +1 617-404-7816 jeanette.bressi@morphosys.com	Myles Clouston Senior Director Tel: +1 857-772-0240 myles.clouston@morphosys.com

SOURCE: MorphoSys AG

View source version on accesswire.com:
https://www.accesswire.com/648537/MorphoSys-To-Participate-in-UBS-Global-Healthcare-Conference

FAQ

What is the date and time of MorphoSys' participation in the UBS Global Healthcare Conference?

MorphoSys will participate in the UBS Global Healthcare Conference on May 25, 2021, at 7:00 a.m. Eastern Time.

Where can I listen to the MorphoSys fireside chat?

The live audio of the MorphoSys fireside chat can be accessed on their website in the Media and Investors section under Conferences.

What is MorphoSys known for?

MorphoSys is a biopharmaceutical company dedicated to developing innovative therapies for cancer and autoimmune diseases.

What significant products has MorphoSys developed?

MorphoSys developed Monjuvi, which received accelerated FDA approval in July 2020, and Tremfya, which was approved in 2017.

What are the stock symbols for MorphoSys?

The stock symbols for MorphoSys are FSE:MOR and NASDAQ:MOR.